ARTICLE | Clinical News
Veletri epoprostenol regulatory update
July 9, 2012 7:00 AM UTC
FDA approved an sNDA for a second generation formulation of Veletri epoprostenol to treat pulmonary arterial hypertension (PAH) to improve exercise capacity. Actelion plans to launch the prostacyclin ...